Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAmeriHealth Caritas ADHD Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentAmeriHealth CaritasPolicy CCP.1470

    Prescription Digital Therapeutics for Attention Deficit Hyperactivity Disorder

    Customize your policy alerts

    Sign up for AmeriHealth Caritas Policy CCP.1470 alerts

    Get alerted when Policy CCP.1470 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage determinations for prescription digital therapeutics used to treat ADHD. EndeavorRx and Prismira, now marketed as LuminosityRx, are investigational and not medically necessary; medication and behavior management are alternative covered services.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyPrescription Digital Therapeutics for Attention Deficit Hyperactivity Disorder
    Policy CodePolicy CCP.1470
    Change TypeMaterial update
    Effective DateAugust 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDecember 1, 2027
    Key ActionDo not request coverage for EndeavorRx or Prismira/LuminosityRx because they are investigational and not medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    Prismira, now marketed as LuminosityRx, was added as a prescription digital therapeutic considered investigational and not medically necessary.

    2Investigational digital therapeutics
    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA-cleared devices discussed
    A9291Related billing code
    8–17EndeavorRx indicated age
    22–55Prismira/LuminosityRx indicated age

    Coverage Criteria

    Investigational prescription digital therapeutics

    The following prescription digital therapeutics for attention deficit hyperactivity disorder are investigational, not clinically proven, and therefore not medically necessary.

    Noncovered prescription digital therapeutic

    • EndeavorRx: Requested product is EndeavorRx.
    • Prismira/LuminosityRx: Requested product is Prismira, now marketed as LuminosityRx.

    EndeavorRx and Prismira, now marketed as LuminosityRx, are excluded from medically necessary coverage because they are considered investigational/not clinically proven and therefore not medically necessary.

    EndeavorRx is considered investigational/not clinically proven and therefore is not medically necessary.

    Prismira, now marketed as LuminosityRx, is considered investigational/not clinically proven and therefore is not medically necessary.

    Related Coding

    Related codesHCPCS
    A9291Prescription digital cognitive and/or behavioral therapy, FDA-cleared, per course of treatment

    Provider Actions

    Denial Risk

    Coverage denied for EndeavorRx and LuminosityRx

    Coverage is denied when the requested prescription digital therapeutic is EndeavorRx or Prismira, now marketed as LuminosityRx. These products are classified as investigational/not clinically proven and therefore not medically necessary.

    • Do not submit these products as medically necessary covered services.
    • The policy identifies medication, including stimulants and non-stimulants, and behavior management as alternative covered services.

    Clinical Background

    Attention deficit hyperactivity disorder (ADHD) is a psychiatric and neurodevelopmental condition characterized by developmentally inappropriate inattention, hyperactivity, and impulsivity that impair daily functioning. Symptoms may interfere with daily living activities and persist for six months or longer. Digital therapeutics have been proposed to improve attention and executive function, but evidence quality is limited, long-term effectiveness is uncertain, and effects on broader behavioral symptoms may be limited.

    Definitions

    Attention deficit hyperactivity disorder (ADHD)
    Clinical classificationA psychiatric and neurodevelopmental condition that affects a child’s ability to function.
    Core symptomsDevelopmentally inappropriate loss of concentration and focus, inattentiveness, hyperactivity, and impulsivity.
    Functional impactSymptoms interfere with daily living activities.
    DurationSymptoms last six months or longer.
    Digital therapeutics
    DefinitionSoftware applications for clinical use intended to improve attention function.
    Therapeutic setting

    Alternative Treatment Modalities

    Medication and behavior management

    Alternative covered services identified by the policy include:

    Alternative covered ADHD services: Medication, including stimulants and non-stimulants, and behavior management are identified as alternative covered services.

    The policy does not provide additional authorization criteria for these services.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyPrescription Digital Therapeutics for Attention Deficit Hyperactivity Disorder
    Policy CodePolicy CCP.1470
    Change TypeMaterial update
    Effective DateAugust 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDecember 1, 2027
    Key ActionDo not request coverage for EndeavorRx or Prismira/LuminosityRx because they are investigational and not medically necessary.
    SourceLink
    On This Page
    Coverage CriteriaRelated CodingProvider ActionsClinical BackgroundDefinitionsAlternative Treatment Modalities
    Used as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs.
    Potential benefitPatients may demonstrate improvements in attention functioning.
    Limit of effectBenefits may not extend to other behavioral symptoms such as hyperactivity.